Life sciences companies continue to be the target of whistleblower actions, not only on the federal level but the state level as well. This article outlines a recent agreement between Bristol-Myers Squibb (“BMS”) and the State of California, resolving allegations stemming from a whistleblower lawsuit centered on illegal kickbacks.
In July 2016, California Insurance Commissioner Dave Jones reached a $30 million settlement with pharmaceutical company Bristol-Myers Squibb (“BMS”) over allegations of drug marketing fraud and physician kickbacks.54 The origins of the case are similar to other recent whistleblower cases. The whistleblowers in this case were former BristolMyers Squibb sales representatives. This is not what makes the case important.
Read Full Article in the October 2016 Issue of Life Science Compliance Update